-
2024-517091-38-00
3
2025-11-25
Head and neck squamous cell carcinoma
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2025-520478-20-00
5
2025-11-05
Thromboembolic disease
-
2025-520613-31-00
5
2025-10-31
Agitation Associated with Alzheimer’s Disease
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2025-520747-32-00
5
2025-10-29
Mild to moderate Alzheimer’s Disease
-
2023-506296-97-00
5
2025-10-28
Moderate to Severe Plaque Psoriasis
-
2024-519420-25-00
5
2025-10-22
Major Depressive Disorder
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-519883-42-00
5
2025-10-08
Non-small cell lung cancer
-
2024-518714-31-00
5
2025-10-03
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-519875-24-00
5
2025-09-26
Carcinoid syndrome
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-511993-55-00
4
2025-09-18
bile acid diarrhoea (BAD)
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-519814-29-00
4
2025-09-12
Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT